Mind Medicine doesn’t quite satisfy our market cap cutoff of one billion dollars, but we’re also steering clear of them for a similar motive we’re avoiding Compass Pathways. As typical with many biotech stocks, neither of these companies have revenues but. There’s a substantial amount of regulatory possibility associated.Already, the legal